These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 30068375)

  • 1. Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer.
    Li X; Xu Y; Ding Y; Li C; Zhao H; Wang J; Meng S
    Mol Cancer; 2018 Aug; 17(1):113. PubMed ID: 30068375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.
    Lyu H; Wang S; Huang J; Wang B; He Z; Liu B
    Cancer Lett; 2018 Apr; 420():97-108. PubMed ID: 29409974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy-Regulated microRNA-125-HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer.
    Yagishita S; Fujita Y; Kitazono S; Ko R; Nakadate Y; Sawada T; Kitamura Y; Shimoyama T; Maeda Y; Takahashi F; Takahashi K; Tamura T; Koizumi F
    Mol Cancer Ther; 2015 Jun; 14(6):1414-23. PubMed ID: 25833836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
    Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
    Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells.
    Yang L; Li Y; Shen E; Cao F; Li L; Li X; Wang X; Kariminia S; Chang B; Li H; Li Q
    Int J Oncol; 2017 Nov; 51(5):1553-1562. PubMed ID: 29048656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 3'UTR of the pseudogene CYP4Z2P promotes tumor angiogenesis in breast cancer by acting as a ceRNA for CYP4Z1.
    Zheng L; Li X; Gu Y; Lv X; Xi T
    Breast Cancer Res Treat; 2015 Feb; 150(1):105-18. PubMed ID: 25701119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic p95HER2 regulates Na+-HCO3- cotransporter NBCn1 mRNA stability in breast cancer cells via 3'UTR-dependent processes.
    Gorbatenko A; Olesen CW; Loebl N; Sigurdsson HH; Bianchi C; Pedraz-Cuesta E; Christiansen J; Pedersen SF
    Biochem J; 2016 Nov; 473(21):4027-4044. PubMed ID: 27609814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
    Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.
    Ye XM; Zhu HY; Bai WD; Wang T; Wang L; Chen Y; Yang AG; Jia LT
    BMC Cancer; 2014 Feb; 14():134. PubMed ID: 24571711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting HER3 with miR-450b-3p suppresses breast cancer cells proliferation.
    Zhao Z; Li R; Sha S; Wang Q; Mao W; Liu T
    Cancer Biol Ther; 2014 Oct; 15(10):1404-12. PubMed ID: 25046105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
    Kim J; Lee J; Kim C; Choi J; Kim A
    Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enforced expression of hsa-miR-125a-3p in breast cancer cells potentiates docetaxel sensitivity via modulation of BRCA1 signaling.
    Xu X; Lv YG; Yan CY; Yi J; Ling R
    Biochem Biophys Res Commun; 2016 Oct; 479(4):893-900. PubMed ID: 27693788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-HER3 Monoclonal Antibody Inhibits Acquired Trastuzumab-Resistant Gynecologic Cancers.
    Li X; Duan Y; Qiao C; Zhou T; Yu M; Geng J; Feng J; Shen B; Lv M; Li Y
    Technol Cancer Res Treat; 2016 Aug; 15(4):573-82. PubMed ID: 26041400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function.
    Garrett JT; Sutton CR; Kuba MG; Cook RS; Arteaga CL
    Clin Cancer Res; 2013 Feb; 19(3):610-9. PubMed ID: 23224399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.
    Nonagase Y; Yonesaka K; Kawakami H; Watanabe S; Haratani K; Takahama T; Takegawa N; Ueda H; Tanizaki J; Hayashi H; Yoshida T; Takeda M; Chiba Y; Tamura T; Nakagawa K; Tsurutani J
    Oncotarget; 2016 Dec; 7(51):84860-84871. PubMed ID: 27768588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
    De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
    Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance.
    Rezaei Z; Sebzari A; Kordi-Tamandani DM; Dastjerdi K
    DNA Cell Biol; 2019 Feb; 38(2):184-192. PubMed ID: 30702337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer.
    Lipton A; Goodman L; Leitzel K; Cook J; Sperinde J; Haddad M; Köstler WJ; Huang W; Weidler JM; Ali S; Newton A; Fuchs EM; Paquet A; Singer CF; Horvat R; Jin X; Banerjee J; Mukherjee A; Tan Y; Shi Y; Chenna A; Larson J; Lie Y; Sherwood T; Petropoulos CJ; Williams S; Winslow J; Parry G; Bates M
    Breast Cancer Res Treat; 2013 Aug; 141(1):43-53. PubMed ID: 23959396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells.
    Baumann J; Wong J; Sun Y; Conklin DS
    BMC Cancer; 2016 Jul; 16():551. PubMed ID: 27464732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers.
    Baldassarre T; Truesdell P; Craig AW
    Breast Cancer Res; 2017 Oct; 19(1):110. PubMed ID: 28974266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.